Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing to bariatric surgery

Chirurgia (Romania)

Volumn 109, Issue 6, 2012, Pages 772-779

  Pirvulescu, I ^a   Gheorghe, L ^a   Csiki, I ^a   Becheanu, G ^a   Dumbrava M ^a   Fica, S ^b   Martin, S ^b   Sarbu, A ^b   Gheorghe, C ^a   Diculescu, M ^a   Copaescu C ^c  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Delta Hospital   (Romania)

Author keywords

Bariatric surgery; Noninvasive biomarkers; Obese; Steatohepatitis

Indexed keywords

5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; 5-(N-METHYL-N-PROPARGYLAMINOMETHYL)-8-HYDROXYQUINOLINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKERATIN 18; INSULIN; LEPTIN; M65 ANTIGEN, HUMAN; PEPTIDE FRAGMENT; QUINOLINOL DERIVATIVE;

ADULT; ARTICLE; BARIATRIC SURGERY; BIOPSY; BLOOD; BODY MASS; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORBID OBESITY; NEEDLE BIOPSY; NONALCOHOLIC FATTY LIVER; NONPARAMETRIC TEST; OBESITY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADIPONECTIN; ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BIOPSY; BIOPSY, NEEDLE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROXYQUINOLINES; INSULIN; INSULIN RESISTANCE; KERATIN-18; LEPTIN; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY, MORBID; OVERWEIGHT; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874024093     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Aliment Pharmacol Ther. 2011;34(3):274-85. doi: 10.1111/ j.1365-2036.2011.04724.x. Epub 2011 May 30.
3. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005;49(5):289-95. Epub 2005 Aug 2.
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95
5. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-31.
6. World Health Organization. Obesity and overweight. Available from fs311/en/index.html. Accessed January 7, 2009.
7. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8(Suppl 1):4-8.
8. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13(4):511-31.
9. Kleiner DE, Brunt EM, Nan NM, BehlingC, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
10. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42(1):132-8.
11. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4): 865-73.
12. Ariz U, Mato JM, Lu SC, Martinez Chantar ML. Nonalcoholic steatohepatitis, animal models and biomarkers: what is new? Methods Mol Biol. 2010;593:109-36.
13. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F. Gut. 2004;53(5): 750-5.
14. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40 Suppl 1:S34-8.
15. Copaescu C. Laparoscopic Roux-en Y gastric bypass. Chirurgia (Bucur). 2012;107(3):379-88. Romanian
16. Boru C, Silecchia G.. Bariatric emergencies: what the general surgeon should know. Chirurgia (Bucur). 2010;105(4):455-64.
17. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32(3):477-81.
18. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7): 1898-906.
19. Estep JM, Birerdinc, Younossi Z.Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med. 2010; 10(2):166-72.
20. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, et al. C- reactive protein levels in relation to various features on non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55(3):660-5. Epub 2011 Jan 14.
21. Hui JM, Farrell GC, Kench JG, George J. High sensitivity C-reactive protein do not reliably predict the severity histological changes in NAFLD. Hepatology. 2004;39(5):1458-9.
22. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3):313-26. Epub 2010 Oct 30.
23. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut. 2006;55(3):415-24. Epub 2005 Sep 20.
24. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437-43.
25. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-19.
26. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2007;13(6):837-44.
27. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol. 2009;15(35):4387-91.
28. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072-8.
29. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011;54(6):1224-9. Epub 2011 Feb 12.
30. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6(11):1249-54. Epub 2008 Jul 26.
31. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18(11):1430-7. Epub 2008 May 24.
32. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. doi: 10.1002/hep.25762.
33. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134-40.
34. Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg. 2009; 64(6):483-93.
35. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138(11):1240-4.
36. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-49. doi: 10.3109/07853890. 2010.518623. Epub 2010 Nov 2.
37. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
38. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003; 138(11):1240-4.
39. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.Am J Gastroenterol. 2007;102(9):1931-8. Epub 2007 May 19.
40. Nozaki Y, Yoneda M, Higurashi T, et al. High sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. Hepatology. 2007; 46(4 Suppl 1):735A.
41. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007; 42(7):573-82. Epub 2007 Jul 25.
42. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3): 313-26. Epub 2010 Oct 30.
43. Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta. 2011; 412(23-24):2031-6. Epub 2011 Sep 8.
44. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34.
45. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol. 2011;23(6):499-506.
46. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26(2):151-6.
47. Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem. 2009;42(7-8):624-9. Epub 2008 Nov 28